Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:		Last Name:		
Address:		City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	DOB:	E-mail:
Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms			Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.			
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider E-mail:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Dermatologist** ☐ **Gastroenterologist** ☐ **Rheumatologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: Remicade (infliximab) Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required for all requests):

☐ Yes ☐ No Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) (e.g., Olumiant, Otezla, Xeljanz)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis (TB)?

→ ☐ Yes ☐ No Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy?

→ (Check all that apply): ☐ PPD test ☐ interferon-gamma assay (IGRA) ☐ chest x-ray

Please enter the results of the tuberculosis (TB) test: ☐ positive ☐ negative ☐ unknown

If positive, please indicate which applies to the patient:
☐ latent TB and treatment for latent TB has been initiated
☐ latent TB and treatment for latent TB has been completed
☐ latent TB and treatment for latent TB has not been initiated
☐ active TB

Continued on next page

Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ Yes ☐ No Is this infusion request in an outpatient hospital setting?
- ☐ Yes ☐ No Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion?
- ☐ Yes ☐ No Has the patient developed antibodies to infliximab which increases the risk for infusion related reactions?
- ☐ Yes ☐ No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
- ☐ Yes ☐ No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?
  - Please provide a description of the behavioral issue or impairment: _____
- ☐ Yes ☐ No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
  - Please provide a description of the condition: ☐ Cardiopulmonary: _____ ☐ Respiratory: _____ ☐ Renal: _____ ☐ Other: _____

For Initiation Requests (clinical documentation required for all requests):

Acute graft versus host disease

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient experienced an inadequate response to systemic corticosteroids?
- ☐ Yes ☐ No Does the patient have an intolerance or contraindication to corticosteroids?

Ankylosing spondylitis and axial spondyloarthritis

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

Please select which of the following applies to the patient: ☐ Active ankylosing spondylitis (AS) ☐ Active axial spondyloarthritis

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Cimzia) indicated for active ankylosing spondylitis or active axial spondyloarthritis?
- ☐ Yes ☐ No Has the patient experienced an inadequate response with at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs), or has an intolerance or contraindication to at least two NSAIDs?

Please indicate the preferred alternatives for ankylosing spondylitis (AS) or axial spondyloarthritis that have been ineffective, not tolerated, or are contraindicated:

☐ Cosentyx ☐ Enbrel ☐ Humira ☐ Simponi Aria

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
- ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Behçet's disease

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) Otezla or a biologic (e.g., Humira) indicated for the treatment of Behçet's disease?
- ☐ Yes ☐ No Has the patient had an inadequate response to at least one nonbiologic medication for Behçet's disease (e.g., apremilast, colchicine, systemic glucocorticoids, azathioprine)?

Crohn's disease

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?
- Please select: ☐ Supported by the manufacturer's prescribing information
  - ☐ Yes ☐ No Is the requested dose and frequency supported by the manufacturer's prescribing information for the patient's diagnosis?
- ☐ Supported by dosing guidelines found in the compendia or current literature
  - ☐ Yes ☐ No Is the supporting information attached?

☐ Yes ☐ No Has the patient been diagnosed with moderately to severely active Crohn's disease (CD)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for moderately to severely active Crohn's disease?
- ☐ Yes ☐ No Does the patient have fistulizing Crohn's disease?
  - ☐ Yes ☐ No Has the patient tried and had an inadequate response to at least one conventional therapy option?
    - ☐ Yes ☐ No Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate IM or SC, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan], tacrolimus)?
  - Please select: ☐ Sulfasalazine (Azulfidine, Sulfazine) ☐ Metronidazole (Flagyl) ☐ Ciprofloxacin (Cipro) ☐ Prednisone ☐ Budesonide (Entocort EC) ☐ Azathioprine (Azasan, Imuran) ☐ Mercaptopurine (Purinethol) ☐ Methotrexate IM or SQ ☐ Methylprednisolone (Solu-Medrol) ☐ Rifaximin (Xifaxan) ☐ Tacrolimus

Continued on next page

Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

Please indicate the preferred alternatives for Crohn's disease that have been ineffective, not tolerated, or are contraindicated:
☐ Humira ☐ Entyvio ☐ Stelara (intravenous formulation)

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Granulomatosis with polyangiitis (Wegener's granulomatosis)

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient experienced an inadequate response with corticosteroids or immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)?
→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids and immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)?
→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids and immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)?

Hidradenitis suppurativa

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient been diagnosed with severe, refractory hidradenitis suppurativa?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for the treatment of severe, refractory hidradenitis suppurativa?
→ ☐ Yes ☐ No Has the patient experienced an inadequate response after at least 90 days of treatment with oral antibiotics?
→ ☐ Yes ☐ No Has the patient experienced an intolerable adverse effect to oral antibiotics?
→ ☐ Yes ☐ No Does the patient have a contraindication to oral antibiotics?

☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Juvenile idiopathic arthritis

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic disease-modifying antirheumatic drug (DMARD) indicated for juvenile idiopathic arthritis?
→ ☐ Yes ☐ No Has the patient experienced an inadequate response to ANY of the following?
→ Please select: ☐ At least 1-month trial of NSAIDs ☐ At least 2 weeks of treatment with corticosteroids (e.g., prednisone, methylprednisolone) ☐ At least 3 months of treatment with methotrexate ☐ At least 3 months of treatment with leflunomide

☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?

☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Enbrel?

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Immune checkpoint inhibitor (e.g., CTLA-4, PD-L1 inhibitor) toxicity

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient experienced an inadequate response to corticosteroids?
→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids?
→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids?
→ ☐ Yes ☐ No Does the patient have cardiac toxicity?
→ ☐ Yes ☐ No Does the patient have moderate or severe diarrhea or colitis?

Continued on next page

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

Plaque psoriasis

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Has the patient been diagnosed with moderate to severe plaque psoriasis?

☐ Yes ☐ No Has the patient ever received (including current utilizers) Otezla or a biologic (e.g., Humira) indicated for the treatment of moderate to severe plaque psoriasis?

→ ☐ Yes ☐ No Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected?

→ Please indicate the percentage of body surface area (BSA) affected (prior to starting the requested medication): _____%

If less than 10% of BSA:

☐ Yes ☐ No Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin?

→ ☐ Yes ☐ No Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin?

→ Please indicate clinical reason to avoid pharmacologic treatment: ☐ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease ☐ Breastfeeding ☐ Cannot be used due to risk of treatment-related toxicity ☐ Drug interaction ☐ Pregnancy or currently planning pregnancy ☐ Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension) ☐ Other, please explain: _____

Please indicate the preferred alternatives for plaque psoriasis that have been ineffective, not tolerated, or are contraindicated:

☐ Humira ☐ Ilumya ☐ Otezla ☐ Skyrizi ☐ Stelara SQ ☐ Taltz ☐ Tremfya

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Psoriatic arthritis

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Has the patient been diagnosed with active psoriatic arthritis (PsA)?

Please indicate which of the following applies to the patient: ☐ WITH co-existent plaque psoriasis ☐ WITHOUT co-existent plaque psoriasis

Please indicate the preferred alternatives for psoriatic arthritis that have been ineffective, not tolerated, or are contraindicated:

☐ Cosentyx ☐ Enbrel ☐ Humira ☐ Otezla ☐ Simponi Aria

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Pyoderma gangrenosum

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for the treatment of pyoderma gangrenosum?

→ ☐ Yes ☐ No Has the patient experienced an inadequate response with corticosteroids or immunosuppressive therapy (e.g., cyclosporine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids and immunosuppressive therapy (e.g., cyclosporine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids and immunosuppressive therapy (e.g., cyclosporine, mycophenolate mofetil)?

Reactive arthritis

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Enbrel) indicated for the treatment of reactive arthritis?

→ ☐ Yes ☐ No Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate at a dose greater than or equal to 15 mg per week?

→ ☐ Yes ☐ No Has the patient experienced intolerance to methotrexate?

→ ☐ Yes ☐ No Does the patient have a contraindication to methotrexate?

→ Please indicate the contraindication: ☐ History of intolerance or adverse event ☐ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease ☐ Elevated liver transaminases ☐ Interstitial pneumonitis or clinically significant pulmonary fibrosis ☐ Renal impairment ☐ Pregnancy or currently planning pregnancy ☐ Breastfeeding ☐ Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia) ☐ Myelodysplasia ☐ Hypersensitivity ☐ Significant drug interaction ☐ Other, please explain: _____

Continued on next page

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

Rheumatoid arthritis

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

→ Please select: ☐ Supported by the manufacturer's prescribing information

→ ☐ Yes ☐ No Is the requested dose and frequency supported by the manufacturer's prescribing information for the patient's diagnosis?

☐ Supported by dosing guidelines found in the compendia or current literature

→ ☐ Yes ☐ No Is the supporting information attached?

☐ Yes ☐ No Has the patient been diagnosed with moderately to severely active rheumatoid arthritis (RA)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic disease modifying drug (e.g., Rinvoq, Xeljanz) indicated for moderately to severely active rheumatoid arthritis?

→ ☐ Yes ☐ No Does the patient meet either of the following: a) the patient was tested for the rheumatoid factor (RF) biomarker and the RF biomarker test was positive, or b) the patient was tested for the anti-cyclic citrullinated peptide (anti-CCP) biomarker and the anti-CCP biomarker test was positive?

→ ☐ Yes ☐ No Has the patient been tested for all of the following biomarkers: a) rheumatoid factor (RF), b) anti-cyclic citrullinated peptide (anti-CCP), and c) C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)?

☐ Yes ☐ No Is the requested medication being prescribed in combination with methotrexate or leflunomide?

→ Please indicate a clinical reason for the patient to not use methotrexate or leflunomide: ☐ History of intolerance or adverse event ☐ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease ☐ Elevated liver transaminases ☐ Interstitial pneumonitis or clinically significant pulmonary fibrosis ☐ Renal impairment ☐ Pregnancy or currently planning pregnancy ☐ Breastfeeding ☐ Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia) ☐ Myelodysplasia ☐ Hypersensitivity ☐ Significant drug interaction ☐ Other, please explain: _____

☐ Yes ☐ No Does the patient have other reason or no clinical reason not to use methotrexate or leflunomide?

↓

→ ☐ Yes ☐ No Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate at a dose greater than or equal to 15 mg per week?

→ ☐ Yes ☐ No Has the patient experienced an intolerance to methotrexate?

→ ☐ Yes ☐ No Does the patient have a contraindication to methotrexate?

Please indicate the contraindication: ☐ History of intolerance or adverse event ☐ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease ☐ Elevated liver transaminases ☐ Interstitial pneumonitis or clinically significant pulmonary fibrosis ☐ Renal impairment ☐ Pregnancy or currently planning pregnancy ☐ Breastfeeding ☐ Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia) ☐ Myelodysplasia ☐ Hypersensitivity ☐ Significant drug interaction ☐ Other, please explain: _____

→ ☐ Yes ☐ No Is the requested medication being prescribed in combination with methotrexate or leflunomide?

→ Please indicate a clinical reason for the patient to not use methotrexate or leflunomide: ☐ History of intolerance or adverse event ☐ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease ☐ Elevated liver transaminases ☐ Interstitial pneumonitis or clinically significant pulmonary fibrosis ☐ Renal impairment ☐ Pregnancy or currently planning pregnancy ☐ Breastfeeding ☐ Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia) ☐ Myelodysplasia ☐ Hypersensitivity ☐ Significant drug interaction ☐ Other, please explain: _____

☐ No clinical reason not to use methotrexate or leflunomide

Please indicate the preferred alternatives for rheumatoid arthritis have been ineffective, not tolerated, or are contraindicated:

☐ Enbrel ☐ Humira ☐ Kevzara ☐ Rinvoq ☐ Simponi Aria ☐ Xeljanz/Xeljanz XR

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Sarcoidosis

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient experienced an inadequate response with corticosteroids or immunosuppressive therapy (e.g., azathioprine, methotrexate)?

→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids and immunosuppressive therapy (e.g., azathioprine, methotrexate?

→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids and immunosuppressive therapy (e.g., azathioprine, methotrexate?

Continued on next page

Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

Takayasu's arteritis

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient been diagnosed with refractory Takayasu's arteritis?

☐ Yes ☐ No Has the patient experienced an inadequate response with corticosteroids or immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids and immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids and immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

Ulcerative colitis

Please indicate loading dose at weeks 0, 2 and 6: _____ Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Has the patient been diagnosed with moderately to severely active ulcerative colitis (UC)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic drug (e.g., Xeljanz) indicated for moderately to severely active ulcerative colitis?

→ ☐ Yes ☐ No Has the patient been hospitalized for acute severe ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)?

→ ☐ Yes ☐ No Has the patient tried and had an inadequate response to at least one conventional therapy option?

→ ☐ Yes ☐ No Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid, hydrocortisone, methylprednisolone [Medrol, Solu-Medrol], prednisone, cyclosporine [Sandimmune], mesalamine [e.g.,Apriso, Asacol, Lialda, Pentasa, Canasa, Rowasa] balsalazide, or olsalazine], mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf])?

→ Please select: ☐ Azathioprine (Azasan, Imuran) ☐ Corticosteroid (e.g., hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone) ☐ Cyclosporine (Sandimmune) ☐ Mesalamine (e.g., Apriso, Asacol, Lialda, Pentas, Canasa, Rowasa) balsalazide, or olsalazine ☐ Mercaptopurine (Purinethol) ☐ Sulfasalazine ☐ Tacrolimus (Prograf)

Please indicate the preferred alternatives for ulcerative colitis that have been ineffective, not tolerated, or are contraindicated:

☐ Humira ☐ Entyvio ☐ Xeljanz/Xeljanz XR ☐ Stelara (intravenous formulation)

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Uveitis

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

☐ Yes ☐ No Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for the treatment of uveitis?

→ ☐ Yes ☐ No Has the patient experienced an inadequate response with corticosteroids or immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids and immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids and immunosuppressive therapy (e.g., methotrexate, azathioprine, mycophenolate mofetil)?

☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?

→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

For Continuation Requests (clinical documentation required for all requests):

Please indicate maintenance dose: _____ frequency: _____weeks

☐ Yes ☐ No Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?

☐ Yes ☐ No Is the requested quantity supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines)?

→ Please select: ☐ Supported by the manufacturer's prescribing information

→ ☐ Yes ☐ No Is the requested dose and frequency supported by the manufacturer's prescribing information for the patient's diagnosis?

☐ Supported by dosing guidelines found in the compendia or current literature

→ ☐ Yes ☐ No Is the supporting information attached?

Continued on next page

Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

For All Conditions (Exception Crohns and Rheumatoid arthritis)

☐ Yes ☐ No Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?

For Crohn's disease, Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Axial spondylitis, Psoriatic arthritis, Plaque psoriasis, Juvenile idiopathic arthritis or Uveitis Only:

☐ Yes ☐ No Has the patient tried and failed treatment with Inflectra (infliximab-dyyb) due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
→ ☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medication)?

Acute graft versus host disease

☐ Yes ☐ No Has the patient experienced an inadequate response to systemic corticosteroids?
→ ☐ Yes ☐ No Does the patient have an intolerance or contraindication to corticosteroids?

Ankylosing spondylitis and axial spondyloarthritis

Please indicate which of the following the patient has experienced an improvement in from baseline:
☐ functional status ☐ total spinal pain ☐ inflammation (e.g., morning stiffness) ☐ none of the above

Please indicate the preferred alternatives for ankylosing spondylitis (AS) or axial spondyloarthritis that have been ineffective, not tolerated, or are contraindicated:
☐ Cosentyx ☐ Enbrel ☐ Humira ☐ Simponi Aria

Crohn's disease

☐ Yes ☐ No Is this a request for a change in dosing regimen?
☐ Yes ☐ No For dosage requests above 5mg only: Does the prescriber recognize that a dose above 5 mg/kg is a high dose and the prescriber confirms that appropriate monitoring will be done?
☐ Yes ☐ No Does the patient require a dose above 5 mg per kg due to loss of response at the current dose?
☐ Yes ☐ No Does the prescribed dose exceed 10 mg per kg?
☐ Yes ☐ No Has the patient achieved or maintained remission?
→ ☐ Yes ☐ No Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
→ Please indicate which of the following the patient has experienced an improvement in from baseline:
☐ abdominal pain or tenderness ☐ diarrhea ☐ body weight ☐ abdominal mass ☐ hematocrit
☐ endoscopic appearance of the mucosa ☐ improvement on a disease activity scoring tool (e.g., Crohn's disease Activity Index [CDAI] score) ☐ none of the above

Please indicate the preferred alternatives for Crohn's disease that have been ineffective, not tolerated, or are contraindicated:
☐ Humira ☐ Entyvio ☐ Stelara (intravenous formulation)

Hidradenitis suppurativa

Please indicate which of the following the patient has experienced since starting treatment with the requested drug:
☐ reduction in abscess and inflammatory nodule count from baseline ☐ reduced formation of new sinus tracts and scarring
☐ decrease in frequency of inflammatory lesions from baseline ☐ reduction in pain from baseline ☐ reduction in suppuration from baseline
☐ improvement in frequency of relapses from baseline ☐ improvement in quality of life from baseline
☐ improvement on a disease severity assessment tool from baseline ☐ none of the above
☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?

Immune checkpoint inhibitor toxicity

☐ Yes ☐ No Has the patient experienced an inadequate response to corticosteroids?
→ ☐ Yes ☐ No Has the patient experienced an intolerance to corticosteroids?
→ ☐ Yes ☐ No Does the patient have a contraindication to corticosteroids?
→ ☐ Yes ☐ No Does the patient have cardiac toxicity?

Juvenile idiopathic arthritis

Please indicate which of the following the patient has experienced an improvement in from baseline:
☐ number of joints with active arthritis (e.g., swelling, pain, limitation of motion) ☐ number of joints with limitation of movement
☐ functional ability ☐ none of the above
☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?
☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Enbrel?

Plaque psoriasis

☐ Yes ☐ No Has the patient experienced a reduction in body surface area (BSA) affected from baseline?
→ ☐ Yes ☐ No Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)?

Please indicate the preferred alternatives for plaque psoriasis that have been ineffective, not tolerated, or are contraindicated:
☐ Humira ☐ Ilumya ☐ Otezla ☐ Skyrizi ☐ Stelara SQ ☐ Taltz ☐ Tremfya

Psoriatic arthritis

Please indicate which of the following the patient has experienced an improvement in from baseline:
☐ number of swollen joints ☐ number of tender joints ☐ dactylitis ☐ enthesitis ☐ skin and/or nail involvement ☐ none of the above

Please indicate the preferred alternatives for psoriatic arthritis that have been ineffective, not tolerated, or are contraindicated:
☐ Cosentyx ☐ Enbrel ☐ Humira ☐ Otezla ☐ Simponi Aria

Reactive arthritis

☐ Yes ☐ No Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition (e.g., tender joint count, swollen joint count, or pain)?

Continued on next page

Remicade® (infliximab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests

Rheumatoid arthritis

☐ Yes ☐ No Is this a request for a change in dosing regimen?
☐ Yes ☐ No Does the patient require a dose above 3 mg per kg due to an incomplete response at the current dose?
☐ Yes ☐ No Does the prescribed dose exceed 10 mg per kg?
☐ Yes ☐ No Has the patient achieved or maintained positive clinical response since starting treatment with the requested drug?
→ Please indicate the percent of disease activity improvement from baseline in tender joint count, swollen joint count, pain, or disability: _____ %
☐ Yes ☐ No Does the patient require dosing more frequent than every 8 weeks due to an incomplete response at the current dosing frequency?

Please indicate the preferred alternatives for rheumatoid arthritis have been ineffective, not tolerated, or are contraindicated:
☐ Enbrel ☐ Humira ☐ Kevzara ☐ Rinvoq ☐ Simponi Aria ☐ Xeljanz/Xeljanz XR

Ulcerative colitis:

☐ Yes ☐ No For dosage requests above 5mg only: Does the prescriber recognize that a dose above 5 mg/kg is a high dose and the prescriber confirms that appropriate monitoring will be done?
☐ Yes ☐ No Has the patient achieved or maintained remission?
→ Please indicate which of the following the patient experienced from baseline: ☐ stool frequency ☐ rectal bleeding
☐ C-reactive protein (CRP) ☐ fecal calprotectin (FC) ☐ endoscopic appearance of the mucosa ☐ urgency of defecation
☐ improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo Score])
☐ none of the above

Please indicate the preferred alternatives for ulcerative colitis that have been ineffective, not tolerated, or are contraindicated:
☐ Humira ☐ Entyvio ☐ Xeljanz ☐ Stelara (intravenous formulation)

Uveitis

Please indicate which of the following the patient has experienced since starting treatment with the requested drug:
☐ reduced frequency of recurrence compared to baseline ☐ decreased reliance on topical corticosteroids
☐ zero anterior chamber inflammation or reduction in anterior chamber inflammation compared to baseline ☐ none of the above
☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Humira?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.